CVD Newswatch, January 16



CVD Healthcare News

U.S. May Soon Face Shortage of General Surgeons

It is expected that general surgeons will soon be in short supply. And this could be as soon as two years’ time. General surgeons are the ones who perform interventions in the emergency room, interventions which save lives. A shortage of these medical professionals would mean even longer waiting time at the ER. And why the shortage? Specialization and the fact that workload wear out doctors fast. We all love hospital dramas from ER to Grey’s Anatomy to Dr. House. A general surgeon’s life can be much harder that what is shown on TV, without the romance and the glamour.

CVD Obesity News

Obesity on the Rise in the U.S.

This audio podcast by the Agency for Healthcare Research and Quality (AHQR) gives a nice overview about the problem of obesity and what we can do to prevent it. Join AHQR Director Dr. Carolyn Clancy for this Healthcare 411 podcast.

CVD Pharma News

WSJ report highlights GlaxoSmithKline concerns with rosiglitazone

Remember the diabetic Avandia (rosiglitazone) and the publication leak story? The Wall Street Journal (WJS) obtained internal emails indicating that researchers at the drug manufacturer GlaxoSmithKline (GSK) had already concerns about the drug’s cardiovascular effect even before the story broke out. GSK claims says “it did not attempt to conceal its own meta-analysis showing similar trends as the study by Nissen and Wolski” which publicly pointed out the health risks of the drug. The US FDA has decided to keep the drug in the market while it is still analysing the data. However, the regulatory body already received documentations from GSK long before the Nissen’s paper came out, according to WSJ.

CVD Journal News

Special Circulation issue dedicated to CVD in Asia

The journal Circulation has dedicated a special issue on cardiovascular disease in Asia. “The presentation of disease there [in Asia] is often different from that seen in the West, and responses to treatment can also differ, necessitating separate study in Asian populations. And given that it is now widely acknowledged that 85% of cardiovascular deaths worldwide will soon occur in low- and middle-income countries, there is a pressing need for such research.

CVD Regulatory News

FDA supports use of Vytorin, completes year-long review of ENHANCE

The US FDA is finally done with reviewing the controversial data of the ENHANCE and issued a statement that Vytorin and other cholesterol-lowering drugs stay, at least for the moment. Vytorin is a combination of the two drugs ezetimibe/simvastatin, which although significantly lowered LDL-cholesterol levels, “did not translate into a significant improvement in carotid IMT.” Results of a similar study IMPROVE IT are being awaited in 2012.

 

Photo credit: stock.xchng

Related Posts with Thumbnails
Print Friendly

Speak Your Mind

*


*

NOTE: The contents in this blog are for informational purposes only, and should not be construed as medical advice, diagnosis, treatment or a substitute for professional care. Always seek the advice of your physician or other qualified health professional before making changes to any existing treatment or program. Some of the information presented in this blog may already be out of date.
Read previous post:
Life after stroke: your coping style counts!

Life after suffering from stroke is hard enough physically. However, certain psychological and social factors seem to make life even...

Close